cetuximab + bevacizumab

This is a combination therapy consisting of the monoclonal antibodies cetuximab and bevacizumab, specifically being evaluated by the University of Miami for the treatment of pediatric relapsed or refractory intracranial gliomas. Cetuximab is a chimeric monoclonal antibody that inhibits the epidermal growth factor receptor (EGFR), while bevacizumab is a humanized monoclonal antibody that targets vascular endothelial growth factor (VEGF) to inhibit angiogenesis. The treatment is administered via super-selective intra-arterial cerebral infusion (SIACI) following blood-brain barrier disruption with mannitol, a technique designed to enhance drug delivery directly to the tumor site while minimizing systemic toxicity. It is being studied in patients under 22 years of age with various high-grade gliomas, including glioblastoma multiforme and diffuse intrinsic pontine glioma (DIPG).

Brand names

ErbituxAvastin

Other names

SIACI of cetuximab and bevacizumabcetuximab and bevacizumab